Telix Pharmaceuticals (ASX:TLX) Presentation, FNN Investor Event, May 2019, Sydney

Company Presentations

Telix Pharmaceuticals Limited (ASX:TLX) CEO, Dr Christian Behrenbruch discusses the company’s development pipeline and the benefit of diagnostic and therapeutic products to deliver correct doses.

Key points:
  • Founded in 2015 by experienced nuclear medicine executives
  • Develops diagnostic and therapeutic radiopharmaceuticals
  • Specialises in metastatic prostate cancer, renal cell cancer, brain cancer
  • Early revenue generation from prostate cancer imaging product
  • Prostate cancer radionuclide therapy is $2b opportunity
  • Renal cancer patients are often mis-staged, a niche $250m opportunity
  • The treatment of GBM is a $300m market opportunity

For more, watch CEO Dr Christian Behrenbruch present at FNN's Investor Event. 

Subscribe to our Daily Newsletter?

Would you like to receive our daily news to your inbox?